Clinical and epidemiologic burden of chronic myelogenous leukemia

References

• Goldman J. ABC of clinical haematology. Chronic myeloid leukaemia. BE Merl 314(7081), 657–660 (1997).
   Google Scholar
• Rector JT, Veillon DM, Schumacher HR, Cotelingam JD. The chronic leukemias of myeloid origin. Merl Lab. Observer30(12), 28 (1998).
   Google Scholar
• Sawyers CL. Chronic myeloid leukemia. N. Engl. Med 340(17), 1330–1340 (1999).
   Google Scholar
• Deisseroth AB, Kantarjian HM, Andreeff M et al Cancer: Principles and Practice of Oncology 5th edition. Lippincott Williams & Wilkins, PA, USA (1997).
   Google Scholar
• Faderl S, Kantarjian HM, Talpaz M, O'Brien S. New treatment approaches for chronic myelogenous leukemia. Semin. Oncol 27(5), 578–586 (2000).
   Google Scholar
• McGuire TR, Kazakoff PW. Phalmacothempy: A Pathophysiologic Approach, 4th edition. Elsevier, NY, USA (1999).
   Google Scholar
• Parkin DM, Whelan SL, Feraly J, Raymond L, Young J. Cancer Incidence in Five Continents, Volume VII IARC Scientific Publication number 143, Lyon, France (1997).
   Google Scholar
• Ries LAG, Eisner MP, Kosary CL et al SEER Cancer Statistics Revietv 1973-1999. National Cancer Institute, MD, USA (2002).
   Google Scholar
• Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantaijian HM. The biology of chronic myeloid leukemia. N Engl Med. 341(3), 164–172 (1999).
   PubMed Web of Science ®Google Scholar
• Lee SJ. Chronic myelogenous leukaemia. Br. kkematol 111(4), 993–1009 (2000).
   PubMedGoogle Scholar
• Silver RT, Woolf SH, Hehlmann R et al An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 94(5), 1517–1536 (1999).
   PubMed Web of Science ®Google Scholar
• ••Comprehensive review of clinical researchby an expert panel convened by the American Society of Hematology to better understand the benefits and risks of established therapies.
   Google Scholar
• Faderl S, Talpaz M, Estrov Z, Kantaijian HM. Chronic myelogenous leukemia: biology and therapy. Ann. Intern. Med. 131(3), 207–219 (1999).
   Google Scholar
• Australian Institute of Health and Welfare (AIHW) and Australasian Association of Cancer Registries (AACR). Cancer in Australia 1998 AIHW, Canberra, Australia (2001).
   Google Scholar
• Gratwohl A, Hermans J, Goldman JM et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 352 (9134), 1087–1092 (1998).
   PubMed Web of Science ®Google Scholar
• Pigneux A, Tanguy ML, Michallet M et al. Prior treatment with CL-interferon does not adversely affect the outcome of allogeneic transplantation for chronic myeloid leukaemia. BE JI-Lematol. 116(1), 193–201 (2002).
   Google Scholar
• Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl. I Med. 344(14), 1031–1037 (2001).
   Google Scholar
• •This presentation of Phase I clinical trial results illustrates the potential for antileukemia pharmaceutical agents based on specific molecular abnormalities of cancer.
   Google Scholar
• Druker BJ, Sawyers CL, Kantaijian H et al. Activity of a specific inhibitor of the BCR- ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Eng.,/ Med. 344(14), 1038–1042 (2001).
   Google Scholar
• Druker BJ, Sawyers CL, Capdeville R, Ford JM, Baccarani M, Goldman JM. Chronic myelogenous leukemia. Hematology Olm. Soc. Hematol Educ. Program) 87–112 (2001).
   Google Scholar
• Talpaz M, Silver RT, Druker BJ et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a Phase 2 study. B/ooc/99(6), 1928-1937 (2002).
   Google Scholar
• Kantarjian HM, Giles FJ, O'Brien SM, Talpaz M. Clinical course and therapy of chronic myelogenous leukemia with interferon-CL and chemotherapy. Hematol Oncol Clin. North Am 12(1), 31–80 (1998).
   Google Scholar
• Horowitz MM, Rowlings PA, Passweg JR. Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 17\(Suppl. 3), S5—S6 (1996).
   Google Scholar
• Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications and toxicities. Oncologist 6 (1), 34–55 (2001) .
   PubMed Web of Science ®Google Scholar
• Sokal JE, Cox EB, Baccarani M et al. Prognostic discrimination in 'good risk' chronic granulocytic leukemia. B/ooc/63(4), 789–799 (1984).
   Google Scholar
• Hehlmann R, Heimpel H, Hasford J et al Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. Blood 82 (2), 398–407 (1993) .
   PubMed Web of Science ®Google Scholar
• Alimena G, Morra E, Lazzarino M et al Interferon a2, as therapy for Ph-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration. B/ooc/72(2), 642–647 (1988).
   Google Scholar
• Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU. Hematologic remission and cytogenetic improvement induced by recombinant human interferon-CL in chronic myelogenous leukemia. N Engl. I Med. 314(17), 1065–1069 (1986).
   Google Scholar
• Talpaz M, Kantarjian HM, McCredie KB, Keating MJ, Trujillo J, Gutterman J. Clinical investigation of human CL-interferon in chronic myelogenous leukemia. B/ooc/69(5), 1280–1288 (1987).
   Google Scholar
• Randomized study on hydroxyurea alone versus hydroxyurea combined with 1 ow-dose interferon-a2b for chronic myeloid leukemia. The Benelux CML Study Group. B/ooc/91(8), 2713–2721 (1998).
   Google Scholar
• Ohnishi K, Ohno R, Tomonaga M et al A randomized trial comparing interferon-CL with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. B/ooc/86(3), 906–916 (1995).
   Google Scholar
• Allan NC, Richards SM, Shepherd PC. UK Medical Research Council randomised, multicentre trial of interferon-CL n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet 345 (8962), 1392–1397 (1995).
   Google Scholar
• Italian Co-operative Study Group on Chronic Myeloid Leukemia. Interferon-a& as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. The Italian Co-operative Study Group on Chronic Myeloid Leukemia. N Engl I Med. 330 (12), 820–825 (1994).
   PubMedGoogle Scholar
• Hehlmann R, Heimpel H, Hasford J et al Randomized comparison of interferon-CL with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. B/ooc/84(12), 4064–4077 (1994).
   Google Scholar
• Chronic Myeloid Leukemia Trialists' Collaborative Group. Interferon-CL versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. Chronic Myeloid Leukemia Trialists' Collaborative Group. Nati Cancer Inst. 89(21), 1616–1620 (1997).
   Google Scholar
• •Example of the use of formal meta-analysis to synthesize the results of individual clinical trials with relatively small patient samples to better understand the cumulative nature of their findings overall and in specific patient subgroups.
   Google Scholar
• Guilhot F, Chastang C, Michallet M et al. Interferon-a2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl Med. 337(4), 223–229 (1997).
   Google Scholar
• Mahon FX, Montastruc M, Faberes C, Reiffers J. Predicting complete cytogenetic response in chronic myelogenous leukemia patients treated with recombinant interferon-a. B/ooc/ 84 (10), 3592–3594 (1994).
   Google Scholar
• McGlave P. The first 1000 unrelated donor transplants for chronic myeloid leukemia: lessons from the National Marrow Donor Program (NMDP) experience. Blood 88\(Suppl. 1), 483a (1996).
   Google Scholar
• Mrsic M, Horowitz MM, Atkinson K et al Second HLA-identical sibling transplants for leukemia recurrence. Bone Marrow Transplant. 9(4), 269–275 (1992).
   Google Scholar
• Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 86(5), 2041–2050 (1995).
   PubMed Web of Science ®Google Scholar
• Arcese W, Goldman JM, D'Arcangelo E et al. Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Chronic Leukemia Working Party. European Bone Marrow Transplantation Group. B/ooc/ 82 (10), 3211–3219 (1993).
   Google Scholar
• Andrykowski MA, Greiner CB, Altmaier EM et al Quality of life following bone marrow transplantation: findings from a multicentre study. Br. Cancer71(6), 1322–1329 (1995).
   Google Scholar
• Kantarjian HM, Talpaz M. Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias. Semin. Oncol 28(5 Suppl. 17), 9–18 (2001).
   Google Scholar
• Druker BJ. Current treatment approaches for chronic myelogenous leukemia. Cancer 1 7\(Suppl. 1), S14—S18 (2001).
   Google Scholar
• Belec RII. Quality of life: perceptions of long-term survivors of bone marrow transplantation. Oncol Nurs. Forum 19(1), 31–37 (1992).
   Google Scholar
• Haberman M, Bush N, Young K, Sullivan KM. Quality of life of adult long-term survivors of bone marrow transplantation: a qualitative analysis of narrative data. Oncol NUTS. Forum 20(10), 1545–1553 (1993).
   Google Scholar
• Carella AM, Frassoni F, Melo J et al New insights in biology and current therapeutic options for patients with chronic myelogenous leukemia. Haematologica 82 (4), 478–495 (1997).
   PubMedGoogle Scholar
• van Rhee F, Szydlo RM, Hermans J et al Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Tramplant20, 553–560 (1977).
   Google Scholar
• Cliff RA, Anasetti C. Allografting for chronic myeloid leukemia. Baillieres Clin. Haematol 10,319–336 (1997).
   PubMedGoogle Scholar
• McGlave P, Bartsch G, Anasetti C et al Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the National Marrow Donor Program. B/ooc/81,543–550 (1993).
   Google Scholar
• Hansen JA, Gooley TA, Martin PJ et al Bone marrow transplants fron unrelated donors for patients with chronic myeloid leukemia. N.Engl. j Merl 338,962–968 (1998).
   PubMed Web of Science ®Google Scholar